Comparison of NCCN and ESMO Guidelines in Locally Advanced Breast Cancer and Implications in a Resource Constrained Healthcare Setting
DOI:
https://doi.org/10.48111/2021.02.06Keywords:
Locally Advanced Breast Cancer, Primary Systemic Therapy, Neoadjuvant Chemotherapy, Survival, Breast CancerAbstract
Locally advanced breast cancer has been associated with poor outcomes in developing countries because of the interplay of multiple factors. The management protocols of this disease are ever-evolving. The aim of this article is to compare NCCN and ESMO guidelines regarding the management of locally advanced breast cancer. The articles for comparative review have been taken from PubMed. The article reviews both protocols in domains of diagnosis, primary systemic therapy, surgery, radiotherapy, adjuvant therapy, and surveillance. Moreover, recommendations in special situations of pregnancy, male population, recurrence, and Covid 19 are mentioned. In addition, the applicability of these guidelines in a healthcare setting with limited tools has been analyzed.
References
Fahad Ullah M. Breast Cancer: Current Perspectives on the Disease Status. In: Advances in Experimental Medicine and Biology. Vol 1152. Springer New York LLC; 2019:51-64. doi:10.1007/978-3-030-20301-6_4
Franceschini G, Terribile D, Fabbri C, Magno S, D’Alba P, Chiesa F, Di Leone A MR. Management of locally advanced breast cancer. Mini-review - PubMed. Minerva Chir. Published 2007. Accessed June 27, 2021. https://pubmed.ncbi.nlm.nih.gov/17641585/
Anis K MS. Bilateral locally advanced metastatic breast cancer at presentation: More work needs to be done! - Journal of Case Reports and Images in Surgery. J Case Rep Images Surg. Published 2021. Accessed June 27, 2021. https://ijcrisurgery.com/archive/article-full-text/100086Z12KA2021
Garg PK, Prakash G. Current definition of locally advanced breast cancer. Curr Oncol. 2015;22(5):e409-e410. doi:10.3747/co.22.2697
B. Y. Overview on locally advanced breast cancer: defining, epidemiology, and overview on neoadjuvant therapy - PubMed. Experimental oncology. Published 2013. Accessed June 27, 2021. https://pubmed.ncbi.nlm.nih.gov/24382433/
Franceschini G, Terribile D, Magno S, Fabbri C, D’Alba PF, Chiesa F, Di Leone A MR. Update in the treatment of locally advanced breast cancer: a multidisciplinary approach - PubMed. Eur Rev Med Pharmacol Sci. Published 2007. Accessed June 27, 2021. https://pubmed.ncbi.nlm.nih.gov/18074936/
Simos D, Clemons M, Ginsburg OM, Jacobs C. Definition and consequences of locally advanced breast cancer. Curr Opin Support Palliat Care. 2014;8(1):33-38. doi:10.1097/SPC.0000000000000020
Sachelarie I, Grossbard ML, Chadha M, Feldman S, Ghesani M, Blum RH. Primary Systemic Therapy of Breast Cancer. Oncologist. 2006;11(6):574-589. doi:10.1634/theoncologist.11-6-574
Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and BRCA2 mutations in a population-based study of breast cancer in White and Black American women ages 35 to 64 years. Cancer Res. 2006;66(16):8297-8308. doi:10.1158/0008-5472.CAN-06-0503
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA - J Am Med Assoc. 2017;317(23):2402-2416. doi:10.1001/jama.2017.7112
Wang H, Mao X. Evaluation of the efficacy of neoadjuvant chemotherapy for breast cancer. Drug Des Devel Ther. 2020;14:2423-2433. doi:10.2147/DDDT.S253961
Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN. Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol. 2007;608:1-22. doi:10.1007/978-0-387-74039-3_1
KR Z. Diagnosis and Treatment of Breast Cancer in Men - PubMed. Radiol Technol. Published 2019. Accessed June 27, 2021. https://pubmed.ncbi.nlm.nih.gov/31471487/
Middleton LP, Amin M, Gwyn K, Theriault R, Sahin A. Breast carcinoma in pregnant women: Assessment of clinicopathologic and immunohistochemical features. Cancer. 2003;98(5):1055-1060. doi:10.1002/cncr.11614
Cardoso F, Harbeck N, Fallowfield L, Kyriakides S, Senkus E. Locally recurrent or metastatic breast cancer: ESMO clinical practice guidelines for diagnosis, treatment, and follow-up. Ann Oncol. 2012;23(SUPPL. 7). doi:10.1093/annonc/mds232
Mathew J, Asgeirsson KS, Cheung KL, Chan S, Dahda A, Robertson JFR. Neoadjuvant chemotherapy for locally advanced breast cancer: A review of the literature and future directions. Eur J Surg Oncol. 2009;35(2):113-122. doi:10.1016/j.ejso.2008.03.015
Iqbal J, Bano K, Saeed A, Akram M AZ. Survival of women with locally advanced breast cancer at a teaching hospital in Lahore - PubMed. J Pak Med Assoc. Published 2010. Accessed June 27, 2021. https://pubmed.ncbi.nlm.nih.gov/21381576/
Mauri D, Pavlidis N, Ioannidis JPA. Neoadjuvant versus adjuvant systemic treatment in breast cancer: A meta-analysis. J Natl Cancer Inst. 2005;97(3):188-194. doi:10.1093/jnci/dji021
Gralow JR, Burstein HJ, Wood W, et al. Preoperative therapy in invasive breast cancer: Pathologic assessment and systemic therapy issues in operable disease. J Clin Oncol. 2008;26(5):814-819. doi:10.1200/JCO.2007.15.3510
Menta A, Fouad TM, Lucci A, et al. Inflammatory Breast Cancer: What to Know About This Unique, Aggressive Breast Cancer. Surg Clin North Am. 2018;98(4):787-800. doi:10.1016/j.suc.2018.03.009
Cardoso F, Costa A, Norton L, et al. ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast. 2014;23(5):489-502. doi:10.1016/j.breast.2014.08.009
IA. M. Clinico-pathological features of breast cancer in Pakistan - PubMed. J Pak Med Assoc. Published 2002. Accessed June 27, 2021. https://pubmed.ncbi.nlm.nih.gov/1207106.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2021 Ahmad Kaleem , Hamna Maryam , Junaid Hassan
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
